Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Brief Smell Identification Test Performance in RBD, DLB and AD
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (5:30 PM-6:30 PM)
10-008

To compare olfaction in participants with the clinical diagnoses of idiopathic REM sleep behavior disorder (RBD), dementia with Lewy bodies (DLB), or Alzheimer’s disease dementia (AD). 

Impaired olfaction has been associated with neurodegenerative diseases and may be a useful tool to aid in diagnosis or track disease progression.

Participants from the Mayo Clinic Alzheimer’s Disease Research Center database who had a diagnosis of RBD, DLB, or AD, and were given the Brief Smell Identification Test (B-SIT). The B-SIT score was calculated as the sum of correct responses. Scores were categorized as reflecting anosmia (<6), hyposmia (6-10), and normal olfactory function (>10). 
We included 161 patients (65% male) comprised of 27 RBD (56% male), 51 DLB (84% male) and 83 AD (47% male). All participants underwent detailed clinical and neuropsychological evaluations at baseline which included MMSE; those with RBD scored 28.8 ± 1.2, DLB scored 23.3 ±4.3, and AD scored 21.5 ±4.9. At initial evaluation, only 22 (14%) of the entire cohort had normal olfactory function. The mean B-SIT total score was significantly lower for DLB (4.5 ± 3.1) compared to RBD (7.5 ± 3.0) or AD (7.0 ± 2.7) (p<0.001) using an ANOVA F-test. Anosmia was present in 76% of DLB, which compared to 32% in RBD, and 32% in AD (p=ns). Hyposmia was present in 18% of DLB, 47% of RBD, and 52% of AD (p=ns). An item analysis illustrated that participants with DLB were less likely to identify Menthol, Clove, Strawberry, Smoke, and Soap than those with RBD and AD.

Impaired olfactory function is frequent in RBD, DLB and AD, with greatest impairment in DLB. Further analyses are needed to determine if any scents are more sensitive to phenotype, progression, and degree of cognitive impairment.
Authors/Disclosures
Leah K. Forsberg, PhD (Mayo Clinic)
PRESENTER 		Ms. Forsberg has nothing to disclose.
Jeremy Syrjanen Jeremy Syrjanen has nothing to disclose.
Tanis J. Ferman, PhD (Mayo Clinic Jacksonville) Ms. Ferman has nothing to disclose.
Bradley F. Boeve, MD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Toji Miyagawa, MD, PhD (Mayo Clinic) Dr. Miyagawa has nothing to disclose.
Neill R. Graff-Radford, MD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic Jacksonville) The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.
David S. Knopman, MD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Jonathan Graff-Radford, MD, FÂ鶹´«Ã½Ó³»­ Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Open evidence . The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member with IMPACT AD .
Rodolfo Savica, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.
David T. Jones, MD (Mayo Clinic) Dr. Jones has stock in Cephlodyne Neurotechnologies, Inc.. Dr. Jones has received intellectual property interests from a discovery or technology relating to health care.
Daniel A. Drubach, MD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) No disclosure on file
Julie A. Fields, PhD (Mayo Clinic) The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute.
Mary M. Machulda, PhD (Mayo Clinic) The institution of Dr. Machulda has received research support from NIH.
John A. Lucas John A. Lucas has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for American Board of Clinical Neuropsychology.
Laura Allen, NP (Mayo Clinic) Ms. Allen has nothing to disclose.
Erik K. St. Louis, MD (Mayo Clinic) The institution of Dr. St. Louis has received research support from NIH. Dr. St. Louis has received publishing royalties from a publication relating to health care. Dr. St. Louis has received publishing royalties from a publication relating to health care.
Michael Silber, MB, ChB, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) Dr. Silber has received publishing royalties from a publication relating to health care. Dr. Silber has received personal compensation in the range of $500-$4,999 for serving as a Topic writer with UpToDate.
Ronald C. Petersen, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.